Innovation Pharmaceuticals Inc (IPIX)

[biodoc]

Short answer: yes

Is it possible that the anti-bacterial and anti-inflammatory properties of B, can make it a more effective therapeutic?

Brilacidin has anti-viral, anti-bacterial, anti-inflammatory and immunomodulatory activity. We have some sense for the anti-viral and anti-bacterial potency but the anti-inflammatory and immunomodulatory properties have been demonstrated in the lab not yet for Covid.

Brilacidin's anti-viral properties may be most important 1) early in the disease process when viral loads are highest or 2) in severely ill patients where the virus seems to linger. Brilacidin's anti-inflammatory and immunomodulatory properties may prove beneficial further in the disease process to limit inflammation and allow for some degree of healing. The anti-bacterial properties may be helpful with secondary bacterial infections which are common in these severely ill patients but these secondary infections are also well covered by existing antibiotics.

Much of the conversation is focused on Brilacidin's anti-viral potency which I believe is only part of the story. Yes, the body has to eliminate the virus and this is why anti-virals have been considered front-line for Covid. However, for patients to get better we need to limit/reverse the tissue damage caused by inflammation, especially in the lungs. Dexamethasone, a potent steroid, has been our best weapon so far and this only provides modest benefit for patients who require supplemental oxygen.

Brilacidins different properties are well demonstrated in the lab. If we talked about what was desirable in a Covid therapeutic I think most scientists would agree that Brilacidin checks off a lot of the different boxes. We don't yet know if this will translate to a meaningful therapeutic benefit.

I'm looking forward to Phase 2 results.